NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.
Locally Advanced and Metastatic Pancreatic Cancer
DRUG: Nanoplatin (NC-6004) and Gemcitabine
Incidence of DLT and Response rate, DLT is evaluated for 3 weeks o the treatment, Response rate is evaluated at 7,13,19 and 25weeks of the treatment
Overall survival, 1.5 year
The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.